The nessecity of hypothalamic pulsatile release of luteinizing hormone-releasing hormone (LHRH) for adequate secretion of ganadotropins is well established (Clark and Cummins, 1982; Santen and Bardin, 1973) . Pulsatile administration of LHRH has been shown to be an effective method for treating patients with hypothalamic hypogonadotropic hypogonadism (Hoffman and Crowley, 1982) . However, we do not have enough information about long-term treatment with LHRH, because LHRH therapy has only recently been developed. In this paper, we report a male patient with hypogonadotropic hypogonadism who has received pulsatile LHRH injections for more than 4 years with successful results. 
Discussion
The patient described here showed increases in concentrations of serum LH and FSH after administration of LHRH intranasally.
However, his plasma T levels did not increase during nasal insufflation of LHRH for 6 months. Mortimer et al.(1974) being continued. After he has the second child, LHRH is going to be replaced by a depot form of testosterone injection. The side effects of LHRH reported are an inflammatory reaction at the infusion site and skin flush. Nakai et al.(1987) reported that 2 of 31 patients who developed a mild skin flush did not need any therapy. It is possible that an antibody to exogenous LHRH is produced and causes a diminished response to LHRH. This patient who has been treated with LHRH for 4 years and 6 months still shows a good response of gonadotropins. As LHRH is a small peptide that is produced by humans themselves, exogenous LHRH is not likely to act as an antigen in patients with LHRH deficiency.
Human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) have been used in treating patients with hypogonadotropic hypogonadism (Finkel et al., 1985) . Klingmuller et al.(1983) compared the effects of long-term treatment with pulsatile LHRH substitution and chronic human hCG administration in patients with Kallmann's syndrome.
They demonstrated that the clinical and endocrine changes associated with puberty could be initiated in patients with Kallman's syndrome by either long-term pulsatile LHRH or hCG treatment, but that LHRH treatment appeared to initiate endocrine changes associated with puberty more rapidly than conventional hCG treatment. hCG in addition to hMG usually increases the sperm count to normal in men with hypogonadotropic hypogonadism of pubertal onset, though in some patients, especially those with cryptorchidism, hCGhMG therapy failed to normalize spermatogenesis (Finkel et al., 1985) . Further studies are necessary to compare the effects of hCG-hMG and pulsatile LHRH in treatment of hypothalamic hypogonadotropic hypogonadism. A serious problem for patients with hypogonadotropic hypogonadism is that they have little opportunity to marry, and even if they get married, they are unlikely to have children.
We expect that pulsatile LHRH therapy, a reasonable and useful tool for treatment of patients with hypothalamic hypogonadotropic hypogonadism, will help to overcome this problem.
